Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. Lyon, France 2020: https://gco.iarc.fr/today. Accessed December 2023.

AIOM-AIRTUM. I numeri del cancro in Italia. Il Pensiero Scientifico Editore; 2021.

Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519-530. https://doi.org/10.1016/j.eururo.2014.10.002 PMID:25449206 DOI: https://doi.org/10.1016/j.eururo.2014.10.002

Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79-87. https://doi.org/10.14740/wjon1279 PMID:32494314 DOI: https://doi.org/10.14740/wjon1279

Powles T, Albiges L, Bex A, et al; ESMO Guidelines Committee. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32(12):1511-1519. https://doi.org/10.1016/j.annonc.2021.09.014 PMID:34597799 DOI: https://doi.org/10.1016/j.annonc.2021.09.014

Choueiri TK, Escudier B, Powles T, et al; METEOR Investigators. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814-1823. https://doi.org/10.1056/NEJMoa1510016 PMID:26406150 DOI: https://doi.org/10.1056/NEJMoa1510016

Choueiri TK, Escudier B, Powles T, et al; METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917-927. https://doi.org/10.1016/S1470-2045(16)30107-3 PMID:27279544 DOI: https://doi.org/10.1016/S1470-2045(16)30107-3

Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35(6):591-597. https://doi.org/10.1200/JCO.2016.70.7398 PMID:28199818 DOI: https://doi.org/10.1200/JCO.2016.70.7398

Choueiri TK, Powles T, Burotto M, et al; CheckMate 9ER Investigators. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829-841. https://doi.org/10.1056/NEJMoa2026982 PMID:33657295 DOI: https://doi.org/10.1056/NEJMoa2026982

Corrao G, Cantarutti A. Building reliable evidence from real-world data: needs, methods, cautiousness and recommendations. Pulm Pharmacol Ther. 2018;53:61-67. https://doi.org/10.1016/j.pupt.2018.09.009 PMID:30253238 DOI: https://doi.org/10.1016/j.pupt.2018.09.009

Escudier B, de Zélicourt M, Bourouina R, Nevoret C, Thiery-Vuillemin A. Management and health resource use of patients with metastatic renal cell carcinoma treated with systemic therapy over 2014-2017 in France: a national real-world study. Clin Genitourin Cancer. 2022;20(6):533-542. https://doi.org/10.1016/j.clgc.2022.07.010 PMID:36050262 DOI: https://doi.org/10.1016/j.clgc.2022.07.010

Hackshaw MD, Nagar SP, Parks DC, Miller LA. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database. J Manag Care Spec Pharm. 2014;20(6):603-610. PMID:24856598 DOI: https://doi.org/10.18553/jmcp.2014.20.6.603

Ronconi G, Dondi L, Piccinni C, et al. Metastatic renal cancer: real-world evidence from a large Italian claims database. Glob Reg Health Technol Assess. 2021;8(1):1-7. https://doi.org/10.33393/grhta.2021.2178 PMID:36627861 DOI: https://doi.org/10.33393/grhta.2021.2178

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481. https://doi.org/10.1080/01621459.1958.10501452 DOI: https://doi.org/10.1080/01621459.1958.10501452

Albiges L, Fléchon A, Chevreau C, et al. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program. Eur J Cancer. 2021;142:102-111. https://doi.org/10.1016/j.ejca.2020.09.030 PMID:33253997 DOI: https://doi.org/10.1016/j.ejca.2020.09.030

Gan CL, Dudani S, Wells JC, et al. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Med. 2021;10(4):1212-1221. https://doi.org/10.1002/cam4.3717 PMID:33463028 DOI: https://doi.org/10.1002/cam4.3717

Maruzzo M, Pierantoni F, Bortolami A, et al. Real-world treatment with nivolumab or cabozantinib for metastatic renal cell carcinoma (mRCC) in the Veneto region of Italy: results of AMOUR study. Target Oncol. 2022;17(4):467-474. https://doi.org/10.1007/s11523-022-00892-z PMID:35751733 DOI: https://doi.org/10.1007/s11523-022-00892-z

Iacovelli R, Ciccarese C, Facchini G, et al. Cabozantinib after a previous immune checkpoint inhibitor in metastatic renal cell carcinoma: a retrospective multi-institutional analysis. Target Oncol. 2020;15(4):495-501. https://doi.org/10.1007/s11523-020-00732-y PMID:32671807 DOI: https://doi.org/10.1007/s11523-020-00732-y

Navani V, Wells JC, Boyne DJ, et al. CABOSEQ: the effectiveness of cabozantinib in patients with treatment refractory advanced renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clin Genitourin Cancer. 2023 Feb;21(1):106.e1-106.e8. https://doi.org/10.1016/j.clgc.2022.07.008 PMID:35945133 DOI: https://doi.org/10.1016/j.clgc.2022.07.008

Santoni M, Heng DY, Bracarda S, et al. Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: focus on sequences and prognostic factors. Cancers (Basel). 2019;12(1):84. https://doi.org/10.3390/cancers12010084 PMID:31905816 DOI: https://doi.org/10.3390/cancers12010084

Shafrin J, Sullivan J, Chou JW, Neely MN, Doan JF, Maclean JR. The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma. Cancer Manag Res. 2017;9:731-739. https://doi.org/10.2147/CMAR.S148199 PMID:29238223 DOI: https://doi.org/10.2147/CMAR.S148199

Italian Medicine Agency (AIFA). National report on medicines use in Italy – Year 2022 Rome, Italy. 2023. https://www.aifa.gov.it/en/-/l-uso-dei-farmaci-in-italia-rapporto-osmed-2022. Accessed June 2024.

Edwards SJ, Wakefield V, Cain P, et al. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2018;22(6):1-278. https://doi.org/10.3310/hta22060 PMID:29393024 DOI: https://doi.org/10.3310/hta22060

Stanisic S, Cicchetti A, Porta C, Procopio G, Berto P. Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia. Glob Reg Health Technol Assess. 2018;5:1-9 . https://doi.org/10.1177/2284240318790734 DOI: https://doi.org/10.33393/grhta.2018.434

Sarrazin MS, Rosenthal GE. Finding pure and simple truths with administrative data. JAMA. 2012;307(13):1433-1435. https://doi.org/10.1001/jama.2012.404 PMID:22474208 DOI: https://doi.org/10.1001/jama.2012.404

Gini R, Schuemie MJ, Pasqua A, et al. Monitoring compliance with standards of care for chronic diseases using healthcare administrative databases in Italy: strengths and limitations. PLoS One. 2017;12(12):e0188377. https://doi.org/10.1371/journal.pone.0188377 PMID:29232365 DOI: https://doi.org/10.1371/journal.pone.0188377

Trifirò G, Gini R, Barone-Adesi F, et al. The role of European healthcare databases for post-marketing drug effectiveness, safety and value evaluation: where does Italy stand? Drug Saf. 2019;42(3):347-363. https://doi.org/10.1007/s40264-018-0732-5 PMID:30269245 DOI: https://doi.org/10.1007/s40264-018-0732-5

Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26(3):155-159. https://doi.org/10.5001/omj.2011.38 PMID:22043406 DOI: https://doi.org/10.5001/omj.2011.38